Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19

• Status: Recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of aerosolized DNase I to remove NETs and decrease respiratory distress in patients with COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane

Criteria

Inclusion Criteria:

• Age ≥18 years old

• Admitted to hospital ward or ICU

• A positive PCR test for SARS-CoV-2 from throat swab or nasopharynx

• An oxygen saturation ≤90% after maximum 15 minutes without supplemental oxygen

• Signed informed consent

Exclusion Criteria:

• Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation

• Known or suspected allergy against Pulmozyme

• Chronic obstructive pulmonary disease stage III-IV or another comparable chronic respiratory disease

• Participation in a clinical study with an investigational product during the last 30 days

• Previous participation in this study

• Pregnancy. Women of childbearing potential must agree to use contraceptives for the duration of the study period

• Any condition that, in the opinion of the Investigator, would place the patient at increased risk or preclude the patient's compliance with the study